How Molecular Testing Helps in Choosing the Right Cancer Treatment

While used as an umbrella term, cancer is not a single disease. It represents a collection of many complex conditions, each driven by different genetic and molecular changes. In recent times, molecular testing for cancer has become a cornerstone in modern oncology. Not only does it allow healthcare providers to look beyond just the cancer’s location, but it also allows them to understand what is happening at a cellular and genetic level. Genomic testing for cancer, by identifying specific mutations, proteins or genetic markers found within a tumour, can therefore offer patients the most effective treatment, customised to their individual condition.

Table of Contents

• What Is Molecular Testing?
• How Molecular Testing Works
• Traditional Cancer Treatment vs Molecular Testing
• Role in Selecting Cancer Treatment
• Benefits of Molecular Testing
• Limitations and Considerations
• Conclusion
• Frequently Asked Questions

What Is Molecular Testing?

Molecular testing is a diagnostic method that looks into a patient’s DNA, RNA, or proteins to scan and pinpoint the genetic root of diseases like cancer. To do so, healthcare providers will create a detailed laboratory analysis of a tissue sample, blood, or other bodily fluids to look for genes, proteins, or molecules that may indicate cancer. Molecular testing can also detect changes in a gene or chromosome that put the patient at high risk of developing cancer and other diseases.

Unlike traditional diagnostic methods that classify cancers primarily based on their location and appearance under the microscope, molecular testing adds a deeper layer of much-needed information, including the specific genetic abnormalities that fuel a tumour.

How Molecular Testing Works

Molecular testing for cancer goes beyond the “one-size-fits-all” approach, allowing healthcare providers to look at the cancer’s specific blueprint and create a highly personalised treatment plan for the patient. By looking at unique biomarkers, oncologists can pinpoint the exact drivers causing your cancer.

These biomarkers reveal details like which genetic mutations are making your cells multiply continuously and rapidly, whether the cancer has a weakness that can be exploited through treatment, or whether the cancer is visible enough to be recognised by the immune system, paving the way for immunotherapy.

The process of molecular testing for cancer begins with tissue extraction, often through a biopsy. Sometimes, blood samples may also be taken. The sample is then analysed in the laboratory to try to detect:

• Gene mutations
• Amplifications or deletions in the DNA sequence
• Chromosomal rearrangements
• Protein expression levels
• How a tumour would respond to certain therapies

Traditional Cancer Treatment vs Molecular Testing

Characteristic	Traditional Cancer Treatment	Molecular Testing for Cancer
Focus of treatment	Depends on the location of the cancer	Depends on the tumour’s specific biomarkers
Patient Grouping	Similar treatment for every patient with the type of cancer	Patients receive treatment based on their individual biomarkers
Style of Therapy	Broad-acting treatments like chemotherapy	Targeted drugs and immunotherapy
Precision	Standard, one-size-fits-all approach	Personalised approach
Expected Results	Effectiveness varies, and side effects are widespread	Higher response potential with more targeted side effects

Role in Selecting Cancer Treatment

Once molecular testing gives out a report, it is treated as a strategy map, allowing healthcare providers to connect your individual biomarkers to the different therapies available that would work best for you. Most of the time, the results point toward one of the two advances in cancer care: targeted therapy and immunotherapy.

Those with EGFR mutations in lung cancer can make use of EGFR-targeted inhibitors instead of standard chemotherapy. Similarly, HER2-positive breast cancer patients can use HER2-targeted therapies. In the case of tumours with high microsatellite instability or mismatch repair deficiency, immunotherapy may be the best option.

Genomic testing for cancer helps match a patient’s tumour with therapies that target the same abnormalities, supporting a more personalised and often more effective treatment strategy and avoiding treatments that are unlikely to work for that particular tumour.

Benefits of Molecular Testing

Molecular testing for cancer has its fair share of advantages over traditional diagnostic methods. Some of them are:

• Improved response rates to treatment: Patients whose molecular markers are compatible with targeted therapies often have better outcomes. Testing can rule out treatments unlikely to work, saving patients from unwanted side effects and delays.
• Individualised Treatments: Molecular testing enables oncologists to create a highly individualised treatment plan for each patient based on their specific biomarkers, as opposed to a “one size fits all” approach.
• Clinical trials eligibility: Molecular profiling can identify candidates for clinical trials targeting specific mutations.
• Disease progression monitoring: Liquid biopsies could also be used to monitor changes in a tumour over time, such as the resistance mutations that develop during treatment.

Limitations & Considerations

Molecular testing in cancer has several advantages. That being said, it’s not without a few limitations. First of all, not every type of cancer may have targetable mutations. Even when mutations are detected, we may not have an appropriate corresponding therapy to target them. Also, a positive response is not always guaranteed. Molecular testing can also be time-consuming; sample quality can affect accuracy, and cost or insurance coverage may be a factor for some patients.

It is smart for patients to discuss the purpose, benefits, and limitations of molecular testing with their oncology team as part of a larger treatment plan.

Conclusion

Cancer molecular testing has transformed the way oncologists create treatment plans, shifting the focus from a generalised model of care to the unique genetic profile of each patient’s specific tumour characteristics. With genomic testing for cancer, physicians can pinpoint particular mutations and biomarkers that can help determine whether targeted therapy, immunotherapy, or standard treatment is the best path forward. Ongoing advances in sequencing technology are likely to lead to an increasing role for molecular testing in improving the precision and outcomes of treatment for cancer patients.

Frequently Asked Questions

Will molecular testing be the same for all cancers?

No. The specific genes or markers tested will depend on the type of cancer, as different cancers are associated with different mutations.

How long do I have to wait to get the results after molecular testing?

Turnaround time depends on the type of test and laboratory, but comprehensive genomic panels typically take one to three weeks.

Will my insurance cover molecular testing?

This totally depends on the insurance provider, type of testing and cancer treatment. Patients should check with their insurance company and care team to have a clear understanding of what is and is not covered.”

Can molecular testing prevent unnecessary chemo?

Sometimes. Some genomic tests, especially for early breast cancer, can help predict the chances of the cancer coming back and whether chemotherapy will probably make a real difference, saving some patients from treatments they might not need.

Can molecular testing be performed on all types of cancer?

Molecular testing can be performed on most solid tumours and blood cancers, but the genes and markers tested will depend on the type of cancer. Some cancers have known actionable mutations, whereas others may have fewer known targetable alterations.